Pharmaceuticals

Enjaymo Market Outlook 2026–2030 advancing with innovation-driven growth

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Enjaymo Market By The End Of 2030?

Historic growth was driven by a scarcity of treatment avenues for CAD, a surge in the diagnosis of uncommon autoimmune diseases, the effectiveness of complement inhibitors, a rise in approvals for orphan drugs, and the proliferation of specialty care facilities.

Expected growth during the forecast period is propelled by factors such as the broadening of complement inhibitor drug portfolios, heightened awareness of uncommon hemolytic illnesses, enhanced diagnostic capabilities, encouraging incentives for orphan drug development, and greater uptake of specialized biologic treatments. Furthermore, major trends anticipated in this period encompass therapies specifically aimed at the complement pathway, an increase in treatments for rare autoimmune diseases, a progression towards precision immunology, a reduction in therapies reliant on transfusions, and expanded development of orphan drugs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20058&type=smp

Which Market Drivers Are Supporting The Expansion Of The Enjaymo Market?

The expansion of the enjaymo market is anticipated to be fueled by the rising occurrence of autoimmune disorders. These conditions arise when the body’s immune system, typically responsible for fighting off threats like bacteria and viruses, erroneously attacks its own healthy tissues and organs. The uptick in autoimmune disorder prevalence is linked to advancements in diagnostics, shifts in environment and diet, sedentary lifestyles, and elements such as chronic stress and the hygiene hypothesis impacting immune system regulation. Enjaymo, a monoclonal antibody treatment, aids individuals with autoimmune disorders by specifically targeting and blocking the C1s component of the complement system. This action stops the immune response activation that leads to red blood cell destruction, thus significantly alleviating hemolytic anemia associated with conditions such as cold agglutinin disease and other autoimmune hemolytic disorders. For example, in February 2024, data from Clinical Trials Arena, a UK-based platform focusing on clinical trials and pharmaceutical developments, indicated that global rheumatoid arthritis (RA) cases are projected to increase dramatically, with prevalence expected to grow by 80.2% and impact nearly 1% of the world’s population by 2050. Consequently, the growing prevalence of autoimmune disorders is propelling the enjaymo market forward.

Enjaymo Market Driver: Rising Clinical Trial Approvals To Drive Enjaymo Market Growth

The enjaymo market is poised for growth due to an increasing volume of clinical trial approvals. These approvals denote the formal permission granted by regulatory bodies for a clinical trial to commence following a review process. The surge in clinical trial approvals is largely attributable to progress in biotechnology, the emergence of biologics, greater involvement from smaller enterprises, and streamlined regulatory pathways designed for addressing rare conditions and unmet medical demands. For therapies like enjaymo, gaining clinical trial approval involves conducting trials, undergoing regulatory scrutiny for safety and effectiveness, and utilizing accelerated routes for rare diseases, subsequently followed by post-market surveillance. As an illustration, in July 2024, the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, representing a 25% rise from the preceding quarter. Thus, the growing number of clinical trial approvals is anticipated to stimulate the expansion of the enjaymo market.

Which Segment Classifications Shape The Enjaymo Market?

The enjaymo market covered in this report is segmented –

1) By Clinical Indication: Cold Agglutinin Disease (CAD), Autoimmune Hemolytic Anemia (AIHA), Complement-Mediated Hemolytic Disorders, Off-Label Uses (Emerging Indications)

2) By Drug Class: Monoclonal Antibodies, Corticosteroids, Immunosuppressants, Other Biological Therapies

3) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

How Are Trends Impacting The Enjaymo Market?

A prominent trend in the enjaymo market involves securing regulatory approvals for medications to enhance treatment availability and ensure adherence to global healthcare standards. Such regulatory approvals signify the official authorization granted by governmental or regulatory bodies, like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), which permits a drug’s marketing and sale. For instance, in January 2023, Sanofi S.A., a pharmaceutical company based in France, obtained FDA approval for Enjaymo (sutimlimab-jome), permitting its use in adults with cold agglutinin disease (CAD) regardless of their transfusion history. Enjaymo functions by targeting the classical complement pathway, thereby preventing the immune system from attacking red blood cells. The updated formulation additionally offers a more convenient administration approach, reducing infusion time to one hour biweekly. This approval represents a substantial advancement in treatment options for CAD patients, ultimately improving their quality of life.

Which Companies Are Expanding Their Footprint In The Enjaymo Market?

Major companies operating in the enjaymo market are Recordati Industria Chimica e Farmaceutica S.p.A.

Read the full enjaymo market report here:

https://www.thebusinessresearchcompany.com/report/enjaymo-global-market-report

How Is The Enjaymo Market Distributed Across Key Geographic Regions?

North America was the largest region in the enjaymo market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the enjaymo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Enjaymo Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20058&type=smp

Browse Through More Reports Similar to the Global Enjaymo Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Esg Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/esg-finance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795